KamLAND, solar antineutrinos and the solar magnetic field

In this work the possibility of detecting solar electron antineutrinos produced by a solar core magnetic field from the KamLAND recent observations is investigated. We find a scaling of the antineutrino probability with respect to the magnetic field profile in the sense that the same probability function can be reproduced by any profile with a suitable peak field value. In this way the solar electron antineutrino spectrum can be unambiguosly predicted. We use this scaling and the negative results indicated by the KamLAND experiment to obtain upper bounds on the solar electron antineutrino flux. We get $\phi_{\bar\nu}<3.8\times 10^{-3}\phi(^8B)$ at 95% CL. For 90% CL this becomes $\phi_{\bar\nu}<3.4\times 10^{-3}\phi(^8B)$, an improvement by a factor of 3-5 with respect to existing bounds. These limits are independent of the detailed structure of the magnetic field in the solar interior. We also derive upper bounds on the peak field value which are uniquely determined for a fixed solar field profile. In the most efficient antineutrino producing case, we get (95% CL) an upper limit on the product of the neutrino magnetic moment by the solar field $\mu B< 2.8\times 10^{-19}$ MeV or $B_0 \leq 4.9 \times 10^7 G$ for $\mu_\nu=10^{-12}\mu_B$.Comment: 15 pages. References corrected. Minor changes in the tex

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

The third edition of Flow Cytometry Guidelines provides the key aspects to consider when performing flow cytometry experiments and includes comprehensive sections describing phenotypes and functional assays of all major human and murine immune cell subsets. Notably, the Guidelines contain helpful tables highlighting phenotypes and key differences between human and murine cells. Another useful feature of this edition is the flow cytometry analysis of clinical samples with examples of flow cytometry applications in the context of autoimmune diseases, cancers as well as acute and chronic infectious diseases. Furthermore, there are sections detailing tips, tricks and pitfalls to avoid. All sections are written and peer-reviewed by leading flow cytometry experts and immunologists, making this edition an essential and state-of-the-art handbook for basic and clinical researchers

Efeito de dinamizações de Arnica montana L. no metabolismo de chambá (Justicia pectoralis Jacq.)

Este estudo objetivou avaliar a resposta do crescimento e do metabolismo secundário de Justicia pectoralis, expresso em produção de cumarina, a crescentes dinamizações de A. montana. O experimento foi conduzido na Universidade Federal de Viçosa. O delineamento estatístico foi inteiramente casualizado, com seis repetições e cinco tratamentos, totalizando 30 parcelas experimentais, sendo cada parcela constituída de uma planta por vaso. Os tratamentos foram as dinamizações 3CH, 30CH, 60CH, 100CH e 200CH do preparado homeopático A. montana. Os tratamentos foram aplicados às plantas via pulverização, em intervalos semanais, iniciando logo após o plantio. Após quatro meses do plantio as plantas foram colhidas. As características de crescimento avaliadas foram matérias fresca e seca de folhas e caules, matérias fresca e seca de inflorescências e matérias fresca e seca total. No estudo fitoquímico foi avaliada a produção da cumarina (1-2 benzopirona). Não houve resposta nas variáveis de crescimento aos tratamentos. As dinamizações de A. montana causaram alterações no metabolismo secundário das plantas. Os conteúdos de cumarina das plantas com A. montana 3CH e 30CH foram próximos e mais baixos, aumentando progressivamente a partir de 60CH, chegando ao máximo em 100CH, seguido de redução em 200CH. A preparação homeopática A. montana causa alterações no metabolismo secundário de chambá, sendo as repostas dependentes da dinamização.Were evaluated the responses to dynamizations of Arnica montana in the growth and in the secondary metabolism of Justicia pectoralis expressed as coumarin production. The studies were carried out at the Universidade Federal de Viçosa. The statistical design was completely randomized, with six replicates and five treatments, 30 experimental plots, one plant per pot. The treatments were dynamizations 3CH, 30CH, 60CH, 100CH and 200CH homeopathic preparation of A. montana. The application the treatments begun are planting seedlings, the aerial part being sprayed, at weekly intervals. After four months of planting, the plants were harvested. The evaluated growth characteristics were: fresh and dry matter of leaves and stems, fresh and dry matter of inflorecenses, and fresh and dry matter total. In the phytochemistry study, the production of the coumarin 1,2-benzopyrone was evaluated. Were no responses of growth characteristics. The dynamizations of A. montana caused changes in secondary metabolism of plants. The coumarin production with A. montana plants 3CH and 30CH were lower, increasing progressively from 60CH, and coming to increased in 100CH, followed by a large reduction in the 200CH. The homeopathic preparation A. montana cause change in secondary metabolism of chambá, and the responses depend on dynamizations